Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.
Stock Price Prediction
Update at 5:00pm EST
4.305 - 4.332
4.332 - 4.351
3.929 - 3.961
3.961 - 3.984
3.998 - 4.045
4.045 - 4.078
as of: 2020-01-17 4:37:57 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.LXRX has closed above bottom band by 34.4%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to LXRX's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
2019-12-03 Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical study. The post Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC appeared first on Investing News Network .
2019-12-02 Why Lexicon Pharma Shares Are Moving Lower Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. Lexicon was co-developing the pipeline asset with Sanofi SA (NASDAQ: SNY ) but has terminated the alliance effective Sept. 9. FDA Firm On Rejection Decision The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for … Full story available on Benzinga.com
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.